Table 3.
Baseline characteristics of a propensity score–matched cohort.
| Variables | Patients not on ACEIs/ARBs (N = 105) n, % | Patients on ACEIs/ARBs (N = 105) n, % | p-Value |
|---|---|---|---|
| Sex male (N/Y) | 73 (69.5) | 75 (71.4) | 0.880 |
| Age (mean ± SD) | 83.48 ± 7.83 | 83.51 ± 5.91 | 0.968 |
| Weight (kg; mean ± SD) | 71.24 ± 17.10 | 70.39 ± 16.41 | 0.724 |
| Body mass index (kg/m2; mean ± SD) | 27.49 ± 6.47 | 27.62 ± 5.74 | 0.875 |
| Systolic blood pressure (mmHg; mean ± SD) | 128.36 ± 20.05 | 133.35 ± 20.95 | 0.079 |
| Diastolic blood pressure (mmHg; mean ± SD) | 70.92 ± 10.65 | 71.98 ± 10.72 | 0.474 |
| Hemoglobin (g; mean ± SD) | 13.00 ± 2.00 | 12.71 ± 1.80 | 0.791 |
| Ejection fraction (mean ± SD) | 53.80 ± 11.93 | 54.41 ± 11.14 | 0.701 |
| Relative wall thickness (mean ± SD) | 0.49 ± 0.10 | 0.49 ± 0.13 | 0.694 |
| Aortic valve area (cm2) | 0.46 ± 0.35 | 0.40 ± 0.32 | 0.253 |
| Heart failure (N/Y) | 38 (36.2) | 37 (35.2) | 1.000 |
| Chronic kidney disease (N/Y) | 45 (42.9) | 42 (40.0) | 0.779 |
| Atrial fibrillation (N/Y) | 40 (38.1) | 37 (35.2) | 0.775 |
| Diabetes (N/Y) | 33 (31.4) | 31 (29.5) | 0.881 |
| Dyslipidemia (N/Y) | 70 (66.7) | 71 (67.6) | 1.000 |
| Smoking (N/Y) | 7 (6.7) | 6 (5.7) | 1.000 |
| Coronary artery disease (N/Y) | 48 (45.7) | 44 (41.9) | 0.676 |
| Peripheral artery disease (N/Y) | 43 (41.0) | 51 (48.6) | 0.331 |
| Chronic obstructive pulmonary disease (N/Y) | 33 (31.4) | 30 (28.6) | 0.763 |
| Beta blockers (N/Y) | 72 (68.6) | 69 (65.7) | 0.769 |
| Alpha blockers (N/Y) | 13 (12.4) | 9 (8.6) | 0.499 |
| Diuretics (N/Y) | 71 (67.6) | 76 (72.4) | 0.547 |
| Calcium channel blockers (N/Y) | 15 (14.3) | 32 (30.5) | 0.008 |
| Antiplatelet therapy (N/Y) | 12 (11.4) | 13 (12.4) | 0.956 |
| NYHA class II (N/Y) | 31 (29.5) | 29 (27.6) | 0.13 |
| NYHA class III (N/Y) | 54 (51.4) | 55 (52.4) | 0.11 |
| NYHA class IV (N/Y) | 20 (19.0) | 21 (20.0) | 0.47 |
| eGFR (mean ± SD) | 57.3 ± 25.0 | 58.1 ± 24.4 | 0.82 |